Form D · Biotechnology

LeukoDx, Inc.

San Jose, CA · CIK 0001470820

Offering snapshot reported Jul 16, 2020 · SEC filing

Reported sold: $5M
Investors reported: 1
Minimum accepted: $5M
First sale: Jul 1, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 16, 2020	Initial	$5,000,000	No comparison	1	SEC filing
Jul 16, 2020	Amendment	$5,000,000	$0vs Jul 16, 2020	1	SEC filing
Aug 2, 2010	Initial	$250,000	No comparison	1	SEC filing
Jun 28, 2010	Initial	$115,000	No comparison	5	SEC filing
Sep 16, 2009	Initial	$377,000	No comparison	12	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-371131

Source: Form D, filed Jul 16, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Mark Chess	Director
Bruce Davis	Director
Walter Drimer	Director
Steve Hurvitz	Director
Harvey Kasdan	Director
Julien Meissonnier	Executive
Nir Nimrodi	Director
Charles Piazza	Director
Michael Reynier	Director
Bruce Sholk	Director
Marvin Slepian	Director
Barry Zubrow	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

2385 Bering Drive
San Jose, CA, 95131